Tenascin-C as a cardiovascular marker
Novel biological markers, such as fibrosis marker galectin-3, peptide hormone adrenomedullin, soluble ST2, chemokine CX3CL1, surrogate marker of vasopressin, and others, are every year one step closer to being introduced into health practice. Over the past decades, significant progress has been made...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«FIRMA «SILICEA» LLC
2022-09-01
|
| Series: | Российский кардиологический журнал |
| Subjects: | |
| Online Access: | https://russjcardiol.elpub.ru/jour/article/view/5150 |
| _version_ | 1797856640728301568 |
|---|---|
| author | A. M. Alieva A. V. Sozykin N. V. Teplova E. V. Reznik D. V. Izimarieva N. A. Novikova I. V. Lozovsky Е. E. Averin R. K. Valiev I. G. Nikitin |
| author_facet | A. M. Alieva A. V. Sozykin N. V. Teplova E. V. Reznik D. V. Izimarieva N. A. Novikova I. V. Lozovsky Е. E. Averin R. K. Valiev I. G. Nikitin |
| author_sort | A. M. Alieva |
| collection | DOAJ |
| description | Novel biological markers, such as fibrosis marker galectin-3, peptide hormone adrenomedullin, soluble ST2, chemokine CX3CL1, surrogate marker of vasopressin, and others, are every year one step closer to being introduced into health practice. Over the past decades, significant progress has been made in the study of cardiovascular biomarkers. A key moment was the introduction of deter mining the concentration of natriuretic peptides used as markers for the diagnostic and prognostic evaluation of patients with heart failure. Currently, in order to search for novel markers for early diagnosis and risk stratification, studies have been conducted on the analysis of promising inflammatory marker tenascin-C (TNC) in cardiovascular patients. Data have been obtained that allow us to consider TNC as a tool for risk stratification and assessment of cardiovascular disease prognosis. The combination of TNC with other biological markers, in particular brain natriuretic peptide, may improve prognostic power. Nevertheless, serial testing to assess the prognosis and effectiveness of ongoing treatment, including in the conditions of a multimarker model, requires further research. |
| first_indexed | 2024-04-09T20:43:41Z |
| format | Article |
| id | doaj.art-c8cd7323053049a1b259f02dd0fea57f |
| institution | Directory Open Access Journal |
| issn | 1560-4071 2618-7620 |
| language | Russian |
| last_indexed | 2024-04-09T20:43:41Z |
| publishDate | 2022-09-01 |
| publisher | «FIRMA «SILICEA» LLC |
| record_format | Article |
| series | Российский кардиологический журнал |
| spelling | doaj.art-c8cd7323053049a1b259f02dd0fea57f2023-03-29T21:23:41Zrus«FIRMA «SILICEA» LLCРоссийский кардиологический журнал1560-40712618-76202022-09-0127810.15829/1560-4071-2022-51503640Tenascin-C as a cardiovascular markerA. M. Alieva0A. V. Sozykin1N. V. Teplova2E. V. Reznik3D. V. Izimarieva4N. A. Novikova5I. V. Lozovsky6Е. E. Averin7R. K. Valiev8I. G. Nikitin9Pirogov Russian National Research Medical UniversityPirogov Russian National Research Medical University; Clinical Research Center № 2 (Central Clinical Hospital of the Russian Academy of Sciences), B.V. Petrovsky Russian Research Center of SurgeryPirogov Russian National Research Medical UniversityPirogov Russian National Research Medical UniversityClinical Research Center № 2 (Central Clinical Hospital of the Russian Academy of Sciences), B.V. Petrovsky Russian Research Center of SurgeryClinical Research Center № 2 (Central Clinical Hospital of the Russian Academy of Sciences), B.V. Petrovsky Russian Research Center of SurgeryClinical Research Center № 2 (Central Clinical Hospital of the Russian Academy of Sciences), B.V. Petrovsky Russian Research Center of SurgeryClinical Research Center № 2 (Central Clinical Hospital of the Russian Academy of Sciences), B.V. Petrovsky Russian Research Center of SurgeryA.S. Loginov Moscow Clinical Research CenterPirogov Russian National Research Medical UniversityNovel biological markers, such as fibrosis marker galectin-3, peptide hormone adrenomedullin, soluble ST2, chemokine CX3CL1, surrogate marker of vasopressin, and others, are every year one step closer to being introduced into health practice. Over the past decades, significant progress has been made in the study of cardiovascular biomarkers. A key moment was the introduction of deter mining the concentration of natriuretic peptides used as markers for the diagnostic and prognostic evaluation of patients with heart failure. Currently, in order to search for novel markers for early diagnosis and risk stratification, studies have been conducted on the analysis of promising inflammatory marker tenascin-C (TNC) in cardiovascular patients. Data have been obtained that allow us to consider TNC as a tool for risk stratification and assessment of cardiovascular disease prognosis. The combination of TNC with other biological markers, in particular brain natriuretic peptide, may improve prognostic power. Nevertheless, serial testing to assess the prognosis and effectiveness of ongoing treatment, including in the conditions of a multimarker model, requires further research.https://russjcardiol.elpub.ru/jour/article/view/5150cardiovascular diseasebiological markerstenascin-cmyocardial infarctionfibrosismyocarditisheart failure |
| spellingShingle | A. M. Alieva A. V. Sozykin N. V. Teplova E. V. Reznik D. V. Izimarieva N. A. Novikova I. V. Lozovsky Е. E. Averin R. K. Valiev I. G. Nikitin Tenascin-C as a cardiovascular marker Российский кардиологический журнал cardiovascular disease biological markers tenascin-c myocardial infarction fibrosis myocarditis heart failure |
| title | Tenascin-C as a cardiovascular marker |
| title_full | Tenascin-C as a cardiovascular marker |
| title_fullStr | Tenascin-C as a cardiovascular marker |
| title_full_unstemmed | Tenascin-C as a cardiovascular marker |
| title_short | Tenascin-C as a cardiovascular marker |
| title_sort | tenascin c as a cardiovascular marker |
| topic | cardiovascular disease biological markers tenascin-c myocardial infarction fibrosis myocarditis heart failure |
| url | https://russjcardiol.elpub.ru/jour/article/view/5150 |
| work_keys_str_mv | AT amalieva tenascincasacardiovascularmarker AT avsozykin tenascincasacardiovascularmarker AT nvteplova tenascincasacardiovascularmarker AT evreznik tenascincasacardiovascularmarker AT dvizimarieva tenascincasacardiovascularmarker AT nanovikova tenascincasacardiovascularmarker AT ivlozovsky tenascincasacardiovascularmarker AT eeaverin tenascincasacardiovascularmarker AT rkvaliev tenascincasacardiovascularmarker AT ignikitin tenascincasacardiovascularmarker |